Biomedical subjects

Hiromitsu Takeyama

Publications and source records attributed to Hiromitsu Takeyama.

40 records · Page 3Linked to original sources

PubMedDate not supplied

Clinicopathological and immunohistochemical analysis of malignant features in mucinous cystic tumors of the pancreas.

BACKGROUND/AIMS: To investigate the malignancy of mucinous cystic tumors (MCTs) of the pancreas, we examined clinicopathological features and immunohistochemical findings of MCT. METHODOLOGY: We analyzed the expression of p53 protein, proliferating cell nuclear antigen, alpha6-integrin subunit, alpha5beta1-integrin, and interleukin-1 receptor type I in tumor specimens from eight patients with MCT. RESULTS: The tumors were classified as mucinous cyst adenoma (n=6) or mucinous cyst adenocarcinoma (n=2). The actuarial five-year survival rate was 83.3%. All in eight MCTs had 'ovarian-type' stroma in the cyst wall. The alpha6-integrin subunit and p53 protein were expressed in adenocarcinoma tissues of MCTs, and in two adenomas the alpha6-integrin subunit and p53 protein were also co-expressed. CONCLUSIONS: Our present results indicate that coexpression of the alpha6-integrin subunit and p53 protein should be appreciated as an indicator of malignancy in MCTs.

Adult↗

PubMedDate not supplied

Surgical treatment for relief of severe pain with chronic pancreatitis that is resistant to conservative treatment.

BACKGROUND/AIMS: To evaluate the surgical treatment, we investigated that performed for chronic pancreatitis patients suffering from severe pain resistant to conservative treatments. METHODOLOGY: Nineteen chronic pancreatitis patients with severe pain resistant for a long time to previous conservative medical and/or interventional treatments underwent surgery retrospectively. We evaluated a difference of postoperative improvement of symptoms in patients with surgical treatment including nerve plexus resection. RESULTS: The mean follow-up interval after surgery was 59.7 months (range, 3.0-187.3 months). Of 19 patients, 14 (73.7%) underwent nerve plexus resection. Relief of symptoms was observed in 16 of 19 patients (84.2%). Fourteen of the 15 patients (93.3%) in the nerve plexus resection group were relieved of symptoms after surgery, compared to only two of four (50.0%) patients in the nerve plexus non-resection group. CONCLUSIONS: Surgical treatments with nerve plexus resection appropriately matched with individual patients are very safe and contribute to the improvement of the quality of life for chronic pancreatitis patients resistant to conservative treatments.

Adult↗

PubMedDate not supplied

Clinicopathologic study of intraductal papillary-mucinous tumors and mucinous cystic tumors of the pancreas.

BACKGROUND/AIMS: We analyzed clinicopathologic and imaging findings of intraductal papillary-mucinous tumors (IPMTs) and mucinous cystic tumors (MCTs) of the pancreas to evaluate the difference between IPMTs and MCTs, and to identify the signs indicative of malignancy in IPMTs. METHODOLOGY: Clinicopathological features of 20 patients with IPMT and six patients with MCT of the pancreas were studied. RESULTS: The patients with IPMT comprised 16 males and four females with a mean age of 62.9 years. Eighty percent of IPMTs were located in the pancreatic head, and the mean tumor size was 38.6mm. Recurrence was observed in one patient, who died of IPM adenocarcinoma. In contrast, all patients with MCT were females, with a mean age of 53.0 years. None of the MCTs arose in the pancreatic head, and the mean tumor size was 42.7mm. One patient died of MC adenocarcinoma, but all of the others survived without recurrence. The difference in gender, location of the tumor, and connection to the pancreatic duct reached statistical significance between IPMTs and MCTs. A significant connection to the pancreatic duct and high level of serum carbohydrate antigen 19-9 (CA19-9) was observed in the adenocarcinoma and moderate dysplasia groups of IPMT. CONCLUSIONS: The main duct type and an elevation of serum CA19-9 level suggested malignancy in IPMTs.

Adenocarcinoma, Mucinous↗

PubMedDate not supplied

Treatment of peritoneal carcinomatosis using carboplatin-loaded hydroxyapatite particles.

UNLABELLED: The anti-tumor effects and tissue distribution of carboplatin (CBDCA) incorporated into hydroxyapatite (HAP) particles was studied. MATERIALS AND METHODS: Seven days after the intraperitoneal (i.p.) implantation of AH130 tumor cells into Donryu rats, the animals were randomized into four groups: group I was treated with saline i.p.; Group II, with CBDCA i.v.; group III with CBDCA i.p.; and group IV with HAP-CBDCA i.p. RESULTS: The survival rate of group IV was better than that of the other groups (p < 0.05). The area under the ascitic platinum concentration-time curve and tissue concentrations of platinum in the omentum after 24 hours of treatment were higher in group IV than in groups II or III (p < 0.05). The platinum concentrations in the kidneys of group IV were lower than in group III (p < 0.05). CONCLUSION: The HAP-CBDCA combination enhances the anti-tumor effects of the drug and reduces the nephrotoxicity in rats with peritoneal carcinomatosis.

Animals↗